Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus ErythematosusReport as inadecuate




Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus - Download this document for free, or read online. Document in PDF available to download.

Autoimmune Diseases - Volume 2014 2014, Article ID 731806, 4 pages -

Research Article

Rheumatology Unit, Fundación Valle del Lili, ICESI University, Carrera 98 18-49, Cali, Colombia

Internal Medicine Unit, Fundación Valle del Lili, CES University, Cali, Colombia

Clinical Research Unit, Fundación Valle del Lili, Cali, Colombia

School of Statistics, Universidad del Valle, Cali, Colombia

Received 3 September 2013; Revised 21 October 2013; Accepted 30 October 2013; Published 16 January 2014

Academic Editor: Juan-Manuel Anaya

Copyright © 2014 Fabio Bonilla-Abadía et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Systemic lupus erythematosus SLE is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab RTX as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment.





Author: Fabio Bonilla-Abadía, Nicolás Coronel Restrepo, Gabriel J. Tobón, Andrés F. Echeverri, Evelyn Muñoz-Buitrón, Andres Mau

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents